Physician profile
Sigrun Hallmeyer
NPI 1164481412
$117,911.39
in general payments reported to CMS, 2019-2025
27 companies · $18K in 2025
The $18K reported for 2025 was more than what 92% of Hematology & Oncology providers received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $45K · 2020: $26K · 2021: $2,118 · 2022: $13K · 2023: $4,273 · 2024: $9,989 · 2025: $18K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $26K · Honoraria: $4,500 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $1,260 · Food and Beverage: $391 · Grant: $250.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $26,165.00 |
| Honoraria | $4,500.00 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $1,260.00 |
| Food and Beverage | $391.12 |
| Grant | $250.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $57,683.88 | 2019-2024 | |
| Astrazeneca Pharmaceuticals LP | $20,588.65 | 2022-2025 | Truqap, Enhertu |
| Gilead Sciences, INC. | $6,187.33 | 2021-2025 | Trodelvy |
| Stemline Therapeutics INC. | $4,960.00 | 2025 | Orserdu |
| Athenex Pharmaceutical Division, LLC | $4,600.00 | 2020 | |
| Immunocore Limited | $4,500.00 | 2025 | Kimmtrak |
| Novartis Pharmaceuticals Corporation | $4,170.23 | 2019-2024 | |
| Array Biopharma INC | $3,060.00 | 2019-2023 | Braftovi |
| Pfizer INC. | $2,743.17 | 2019-2024 | |
| Daiichi Sankyo INC. | $2,047.50 | 2024-2025 | Enhertu |
| Eli Lilly and Company | $1,875.00 | 2023 | |
| Celgene Corporation | $1,840.00 | 2019-2022 | |
| Seagen INC. | $1,375.00 | 2020 | |
| R-Pharm US LLC | $1,370.08 | 2019 | |
| Endomagnetics LTD | $218.34 | 2022 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $214.90 | 2019 | |
| Merit Medical Systems INC | $129.60 | 2022 | |
| Regeneron Healthcare Solutions, INC. | $119.15 | 2019 | |
| Lilly USA, LLC | $105.95 | 2021 | |
| Pharmacyclics LLC, An Abbvie Company | $100.81 | 2019 | |
| Genentech USA, INC. | $21.80 | 2019 |
6 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sigrun Hallmeyer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.